Brought to you by 
Pfizer, Allergan to combine in $160bn deal; merger scrapped due to tax law change
01 Jun 2021
Executive Summary
In the largest merger in the health care industry to date, Pfizer Inc. will pay a whopping $160bn in stock--$363.63 per share (a 20% premium)--for Allergan PLC. Allergan shareholders will receive 11.3 shares in the combined entity for each of their shares. Pfizer stockholders can also choose to receive some cash instead of stock of the combined company, provided the total cash is between $6-12bn (if it's more or less than the two limits, the stock and cash elections will be prorated).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Transdermal
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer, Allergan to combine in $160bn deal; merger scrapped due to tax law change
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice